Compare ADMA Biologics Inc (ADMA) vs Global X NASDAQ 100 Covered Call ETF (QYLD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ADMA Biologics Inc vs Global X NASDAQ 100 Covered Call ETF — how do they compare? ADMA Biologics Inc trades at $9.86 (market cap $2.22B), while Global X NASDAQ 100 Covered Call ETF trades at $18.18. The key difference: Global X NASDAQ 100 Covered Call ETF is trading nearer its 52-week high, ADMA Biologics Inc nearer its low. Which is the better fit depends on your goals.
| ADMA | QYLD | |
|---|---|---|
Market Cap | $2.22B | — |
Sector | Health | Income / Options Overlay |
52-Week High | $20.38 | $18.52 |
52-Week Low | $7.60 | $16.46 |
Enterprise Value | $2.29B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $9.87, up 1.23% today, with a bullish technical signal supported by moving averages. The company reported strong 2025 fundamentals, including $510.17M revenue, 32.98% net income margin, and robust profitability metrics like 41.9% ROE. However, recent Q1 and Q2 2026 earnings missed expectations, and the stock faces significant negative sentiment due to multiple class-action lawsuits alleging securities fraud, with deadlines in August 2026.
The outlook is mixed: strong fundamentals and an 88.89% analyst buy rating support upside, but legal overhangs and earnings misses pose near-term risks. Investors should weigh solid financial health against potential volatility from litigation outcomes and execution consistency.
QYLD trades at $18.185, showing modest daily gains of 0.19% with a bullish technical signal from moving averages despite overbought RSI conditions. The ETF maintains its covered call strategy focus, generating high dividend yields around 12% through systematic options writing on Nasdaq-100 components. Recent dividend payments of $0.18-$0.19 per share demonstrate consistent income distribution to shareholders.
The outlook remains balanced between high income generation and growth limitations. While the 12% yield attracts income-focused investors, long-term underperformance versus the underlying index presents a key trade-off. Market sentiment is divided between yield attractiveness and capital appreciation concerns, requiring careful consideration of investment objectives and risk tolerance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ADMA Biologics Inc
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →About Global X NASDAQ 100 Covered Call ETF
QYLD is an ETF that follows a covered call strategy on the NASDAQ 100 Index. The fund holds a long position in the stocks of the NASDAQ 100 and simultaneously writes (sells) call options on the index. The primary goal is to generate monthly income from the option premiums. This strategy can reduce portfolio volatility and provide income, but it limits potential capital appreciation from a significant rise in the NASDAQ 100 Index.
Read more on QYLD →
